文献速递心力衰竭与心肌病血脂与心血管预防

肾脏疾病患者的心力衰竭

Heart failure in patients with kidney disease.
PubMed 文献 · Heart · 2017-07-17

综述指出心力衰竭是慢性肾脏病患者致病和致死的主要原因,且患病人群持续增长。由于缺乏针对该人群验证的影像和生物标志物,诊断具有挑战性;心肾病理生理复杂且双向,肾脏特异性危险因素促进心衰及肾功能下降,当前心衰治疗在此人群中利用不足。

要点

  • 慢性肾脏病患者心衰患病率高,诊断困难,缺乏验证的影像和生物标志物。
  • 心肾病理生理双向复杂,肾脏特异性危险因素促进心衰及肾功能下降。
  • 当前心衰治疗在慢性肾脏病人群中利用不足,需更靶向治疗及新疗法。

核心结论

  • 心力衰竭是慢性肾脏病患者致病和致死的主要原因,且患病人群持续增长。
  • 当前心衰治疗在慢性肾脏病人群中利用不足,更靶向治疗可能改善预后。
  • 需进一步开发针对慢性肾脏病人群的新型心衰疗法。

研究设计与样本

  • 综述,未报告系统检索范围。

主要发现

  • 慢性肾脏病患者心衰诊断困难,部分因缺乏针对该人群验证的影像和生物标志物。
  • 心肾病理生理复杂且双向,肾脏特异性危险因素包括营养不良、酸碱改变、尿毒症毒素、骨矿物质变化、贫血和心肌顿抑。
  • 这些危险因素也促进亚临床和临床心衰患者的肾功能下降。

临床怎么用

  • 临床需关注慢性肾脏病患者心衰的早期识别与综合管理。
  • 应重视肾脏特异性危险因素对心肾功能双向影响。
  • 当前心衰治疗在慢性肾脏病人群中利用不足,需优化治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Heart failure (HF) is a leading cause of morbidity and mortality in patients with chronic kidney disease (CKD), and the population of CKD patients with concurrent HF continues to grow. The accurate diagnosis of HF is challenging in patients with CKD in part due to a lack of validated imaging and biomarkers specifically in this population. The pathophysiology between the heart and the kidneys is complex and bidirectional. Patients with CKD have greater prevalence of traditional HF risk factors as well as unique kidney-specific risk factors including malnutrition, acid-base alterations, uraemic toxins, bone mineral changes, anemia and myocardial stunning. These risk factors also contribute to the decline of kidney function seen in patients with subclinical and clinical HF. More targeted HF therapies may improve outcomes in patients with kidney disease as current HF therapies are underutilised in this population. Further work is also needed to develop novel HF therapies for the CKD population.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Tuegel C, Bansal N. Heart failure in patients with kidney disease. Heart. 2017. PMID: 28716974. doi:10.1136/heartjnl-2016-310794

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。